Loading...
ALIM logo

Alimera Sciences, Inc.NasdaqGM:ALIM Voorraadrapport

Marktkapitalisatie US$301.3m
Prijs aandeel
n/a
US$5.67
n.v.t.intrinsieke korting
1Y78.1%
7D0.2%
1D
Portefeuillewaarde
​
Bekijk

Alimera Sciences, Inc.

NasdaqGM:ALIM Voorraadrapport

Marktkapitalisatie: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences (ALIM) Aandelenoverzicht

A pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. Meer informatie

Beloningen

Verhandeld tegen 92% onder onze schatting van de reële waarde

De winst zal naar verwachting met 62.74% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt

Aandeelhouders zijn het afgelopen jaar verwaterd


ALIM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Alimera Sciences, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Alimera Sciences
Historische aandelenkoersen
Huidige aandelenkoersUS$5.54
52 Week HoogtepuntUS$5.65
52 Week LaagUS$2.61
Bèta1.25
1 maand verandering-0.89%
3 maanden verandering81.64%
1 Jaar Verandering78.14%
3 jaar verandering18.12%
5 jaar verandering-34.08%
Verandering sinds IPO-96.64%

Recent nieuws en updates

Seeking Alpha • Sep 11

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Summary Alimera Sciences, Inc. is being acquired by ANI Pharmaceuticals for $5.50 per share, with a contingent value right, or CVR, potentially adding up to $0.50 per share. Despite initial delays and Alimera suing ANI to close the deal, ANI remains committed, expecting to resolve closing conditions promptly. The deal is highly synergistic, adding durable assets to ANI's portfolio, with significant revenue growth and accretion expected by 2025. At $5.54 per share, Alimera Sciences stock is attractive, offering potential CVR payouts based on achievable sales targets, making it a compelling investment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Alimera Sciences: Cheap CVR Optionality

Summary Alimera Sciences is being acquired by a larger peer at $5.5/share + CVR of up to 50 cents. In this article, I will focus on a CVR play with only a 10-cent outlay and a potential payout of up to 50 cents. The merger-related risks are minimal, and there are arguments that suggest the CVR milestones could be met. Read the full article on Seeking Alpha
Analyseartikel • Jun 18

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

You may think that with a price-to-sales (or "P/S") ratio of 1.9x Alimera Sciences, Inc. ( NASDAQ:ALIM ) is a stock...

Recent updates

Seeking Alpha • Sep 11

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Summary Alimera Sciences, Inc. is being acquired by ANI Pharmaceuticals for $5.50 per share, with a contingent value right, or CVR, potentially adding up to $0.50 per share. Despite initial delays and Alimera suing ANI to close the deal, ANI remains committed, expecting to resolve closing conditions promptly. The deal is highly synergistic, adding durable assets to ANI's portfolio, with significant revenue growth and accretion expected by 2025. At $5.54 per share, Alimera Sciences stock is attractive, offering potential CVR payouts based on achievable sales targets, making it a compelling investment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Alimera Sciences: Cheap CVR Optionality

Summary Alimera Sciences is being acquired by a larger peer at $5.5/share + CVR of up to 50 cents. In this article, I will focus on a CVR play with only a 10-cent outlay and a potential payout of up to 50 cents. The merger-related risks are minimal, and there are arguments that suggest the CVR milestones could be met. Read the full article on Seeking Alpha
Analyseartikel • Jun 18

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

You may think that with a price-to-sales (or "P/S") ratio of 1.9x Alimera Sciences, Inc. ( NASDAQ:ALIM ) is a stock...
Analyseartikel • Feb 15

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right...
Analyseartikel • Dec 30

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyseartikel • Oct 13

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

There wouldn't be many who think Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.5x is...
Analyseartikel • Sep 13

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Oct 06

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera Sciences (NASDAQ:ALIM) said on Thursday a post-hoc analyses from a Phase 4 study showed that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Iluvien provides diabetic macular edema patients with continuous therapy for up to 36 months. The treatment significantly reduced the number of eyes requiring anti-VEGF, corticosteroid, and laser therapy and reduced the total number of therapies administered by 46%. Iluvien is a intravitreal implant in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Seeking Alpha • Sep 20

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Ireland. ALIM said the reimbursement was granted to the its Ireland-based European unit by the Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland. The reimbursement decision by Ireland adds to a string of such grants earlier this year by Portugal, France and Italy. "We continue to expand the availability of our non-infectious uveitis indication in our International Segment with it now accessible to patients in all of our direct markets in addition to our key distributor markets," ALIM CEO Rick Eiswirth said in a statement. ALIM stock closed -3.6% at $5.38 on Monday.
Seeking Alpha • Aug 09

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal. ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and Health Products with no change to the current label. The reimbursement decision by Portugal follows similar approvals for Iluvien in France and Italy in July. “This summer has been a productive one for expanding availability of our non-infectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets,” ALIM CEO Rick Eiswirth said in a statement. ALIM said it is planning to launch Iluvien in Portugal and France in Q3. Alimera (ALIM) stock closed +2.6% at $7.18 on Monday.
Seeking Alpha • Jul 22

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval for Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products. Alimera (ALIM) did not disclose the pricing determination for Iluvien. Earlier in July, ALIM got Italian regulatory approval and was granted pricing and reimbursement for Iluvien for the same indication. ALIM stock closed +0.8% at $5.33 on Thursday.
Seeking Alpha • Jul 08

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences (NASDAQ:ALIM) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation. ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement for Iluvien by the Italian Medicines Agency (AIFA), Alimera said in a statement on Friday. The indication was for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. ALIM said it would launch Iluvien through its Italian distribution partner, ophthalmic company SIFI. It did not disclose the pricing determination for Iluvien. ALIM stock closed marginally higher at $5.32 on Thursday.
Analyseartikel • Mar 24

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analyseartikel • Nov 06

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alimera Sciences, Inc...
Analyseartikel • Aug 24

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Even though Alimera Sciences, Inc. ( NASDAQ:ALIM ) posted strong earnings recently, the stock hasn't reacted in a large...
Analyseartikel • Feb 11

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences, Inc. ( NASDAQ:ALIM ) shareholders will doubtless be very grateful to see the share price up 97% in...

Rendement voor aandeelhouders

ALIMUS PharmaceuticalsUS Markt
7D0.2%2.7%-2.4%
1Y78.1%38.2%21.5%

Rendement versus industrie: ALIM overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 38.2 % opleverde.

Rendement versus markt: ALIM overtrof de US markt, die het afgelopen jaar een rendement opleverde van 21.5 %.

Prijsvolatiliteit

Is ALIM's price volatile compared to industry and market?
ALIM volatility
ALIM Average Weekly Movement22.1%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: De aandelenkoers van ALIM is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ALIM is het afgelopen jaar gestegen van 13% naar 22%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2003157Rick Eiswirthalimerasciences.com

Alimera Sciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Alimera Sciences zich tot de beurswaarde?
ALIM fundamentele statistieken
MarktkapitalisatieUS$301.29m
Inkomsten(TTM)-US$15.27m
Inkomsten(TTM)US$99.68m
3.0x
P/S-verhouding
-19.7x
Koers/Winstverhouding

Is ALIM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALIM resultatenrekening (TTM)
InkomstenUS$99.68m
Kosten van inkomstenUS$13.57m
BrutowinstUS$86.11m
Overige uitgavenUS$101.39m
Inkomsten-US$15.27m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.28
Brutomarge86.39%
Nettowinstmarge-15.32%
Schuld/Eigen Vermogen Verhouding179.8%

Hoe presteerde ALIM op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/09/18 16:13
Aandelenkoers aan het einde van de dag2024/09/13 00:00
Inkomsten2024/06/30
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Alimera Sciences, Inc. wordt gevolgd door 12 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Caroline CornerCantor Fitzgerald & Co.